

Application No. 10/537,645  
Amendment dated December 18, 2007  
Reply to Office action of November 16, 2007

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Original) (E)-2-(5-Chlorothien-2-yl)-N-((3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl)ethanesulfonamide in substantially crystalline form.
2. (Original) The substantially crystalline form as claimed in claim 1 in the form of needle-shaped crystals.
3. (Original) The substantially crystalline form as claimed in claim 1 in the form of lath-shaped crystals.
4. (Original) The substantially crystalline form as claimed in claim 1 in the form of a mixture of needle-shaped and lath-shaped crystals.
5. (Previously Presented) The substantially crystalline form as claimed in claim 1 wherein the melting point is greater than 160°C.
6. (Original) The substantially crystalline form as claimed in claim 1 having an X-ray powder diffraction pattern expressed in terms of 2 theta angles and obtained with a diffractometer, wherein said X-ray powder diffraction pattern comprises 2 theta angles at one or more positions selected from the group consisting of 9.1-9.2 ( $\pm 0.1$ ), 16.0-16.1 ( $\pm 0.1$ ), 18.0-18.2 ( $\pm 0.1$ ), and 18.3-18.4 ( $\pm 0.1$ ) degrees.
7. (Original) The substantially crystalline form as claimed in claim 1 having an X-ray powder diffraction pattern expressed in terms of 2 theta angles and obtained with a diffractometer, wherein said X-ray powder diffraction pattern comprises 2 theta angles at one or more positions selected from the group consisting of 9.21  $\pm 0.05$ , 13.79  $\pm 0.05$ , 16.11  $\pm 0.05$ , 18.11  $\pm 0.05$ , and 18.39  $\pm 0.05$  degrees.

Application No. 10/537,645  
Amendment dated December 18, 2007  
Reply to Office action of November 16, 2007

8. (Original) The substantially crystalline form as claimed in claim 1 having an X-ray powder diffraction pattern expressed in terms of 2 theta angles and obtained with a diffractometer, wherein said X-ray powder diffraction pattern comprises 2 theta angles at one or more positions selected from the group consisting of  $9.1 \pm 0.1$ ,  $16.0 \pm 0.1$ ,  $18.0 \pm 0.1$ , and  $18.3 \pm 0.1$  degrees.
9. (Original) The substantially crystalline form as claimed in claim 1 for which the X-ray diffraction data are as shown in Table 2.
10. (Original) The substantially crystalline form as claimed in claim 1 for which the X-ray diffraction data are as shown in Table 4.
11. (Original) The substantially crystalline form as claimed in claim 1 for which the X-ray diffraction pattern is as shown in Figure 1.
12. (Original) The substantially crystalline form as claimed in claim 1 for which the X-ray diffraction pattern is as shown in Figure 2.
13. (Previously Presented) A method for the preparation of (E)-2-(5-chlorothien-2-yl)-N-((3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl)ethenesulfonamide in substantially crystalline form which method comprises crystallisation of (E)-2-(5-chlorothien-2-yl)-N-((3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl)ethenesulfonamide from an organic solution, optionally in the presence of water.
14. (Original) A method as claimed in claim 13 wherein the organic solution selected from: an aromatic hydrocarbon, a cycloalkane, an ester, an alcohol or a ketone, or a mixture thereof.
15. (Cancelled).
16. (Cancelled).

Application No. 10/537,645  
Amendment dated December 18, 2007  
Reply to Office action of November 16, 2007

17. (Cancelled).

18. (Cancelled).